BIOHARVEST SCIENCES INC
BHSTNASDAQTrading Snapshot
- Day Range
- $2.12 – $2.17
- 52-Week Range
- $0.14 – $0.38
- Volume
- $4.79B
- Avg Volume
- $5.98B
- Shares Outstanding
- 22.7M
- Next Earnings
- Sep 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $35M
- Last Q Revenue
- $9M
- P/E Ratio
- —
- P/S Ratio
- 3.0x
- EPS (TTM)
- $-1.19
- Dividend Yield
- —
Why Investors Own BHST
- ✓High-growth profile — revenue up +24.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 48% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About BIOHARVEST SCIENCES INC
BioHarvest Sciences Inc. functions as a biotechnology firm with operations segmented into Nutraceuticals and Pharmaceuticals. A key innovation is its proprietary botanical synthesis platform technology, which allows for the cultivation of active ingredients found within plant enzymes or cells. The company harnesses this advanced technology to craft evidence-based and clinically validated therapeutic products for both its nutraceutical and pharmaceutical offerings. Beyond its own development, it also provides contract development and manufacturing services. Its product portfolio includes various wellness items, notably VINIA, a dietary supplement derived from red grape cells, which delivers the full spectrum of polyphenols naturally present in red grapes. The company conducts business in Israel and the United States, with its corporate base in Vancouver, Canada.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Conference Call: BioHarvest Sciences Lowers FY2026 Sales Guidance from $42.000M-$48.000M to $37.000M-$40.000M vs $42.914M Est
BioHarvest Sciences (NASDAQ:BHST) lowers FY2026 sales outlook from $42.000 million-$48.000 million to $37.000 million-$40.000 million vs $42.914 million estimate.
BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript
BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call August 11, 2026 8:00 AM EDTCompany ParticipantsZaki Rakib - Co-Founder, CEO, Executive Chairman &...
BioHarvest Sciences Revises FY26 CDMO Revenue Guidance to $4M-$5M from $4M-$6M; VINIA D2C Revenue Guidance to $33M-$35M from $38M-$42M
BioHarvest Sciences (NASDAQ:BHST) stated that full-year 2026 revenue guidance for its CDMO business has been narrowed to $4 million-$5 million, from $4 million-$6 million previously, while revenue guidance for the VINIA
BioHarvest Sciences Enters Agreement For A Rare, Endangered Fragrance Plant Cell Culture With A UAE-Based Customer; Sees $20M-$30M In 2027-28 Sales
This particular scent is widely regarded as one of the most valuable fragrance raw materials in the world, with premium grades commanding prices exceeding tens of thousands of U.S. dollars per kilogram and demand
BioHarvest Sciences Receives $1.4M Grant Approval From Israel Innovation Authority
BioHarvest Sciences Inc (NASDAQ:BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that the Israel Innovation Authority (IIA) has approved a